Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 187

1.

Somatic MED12 mutations in prostate cancer and uterine leiomyomas promote tumorigenesis through distinct mechanisms.

Kämpjärvi K, Kim NH, Keskitalo S, Clark AD, von Nandelstadh P, Turunen M, Heikkinen T, Park MJ, Mäkinen N, Kivinummi K, Lintula S, Hotakainen K, Nevanlinna H, Hokland P, Böhling T, Bützow R, Böhm J, Mecklin JP, Järvinen H, Kontro M, Visakorpi T, Taipale J, Varjosalo M, Boyer TG, Vahteristo P.

Prostate. 2016 Jan;76(1):22-31. doi: 10.1002/pros.23092. Epub 2015 Sep 18.

PMID:
26383637
2.

Uterine leiomyoma-linked MED12 mutations disrupt mediator-associated CDK activity.

Turunen M, Spaeth JM, Keskitalo S, Park MJ, Kivioja T, Clark AD, Mäkinen N, Gao F, Palin K, Nurkkala H, Vähärautio A, Aavikko M, Kämpjärvi K, Vahteristo P, Kim CA, Aaltonen LA, Varjosalo M, Taipale J, Boyer TG.

Cell Rep. 2014 May 8;7(3):654-60. doi: 10.1016/j.celrep.2014.03.047. Epub 2014 Apr 18.

3.

Mutations in Exon 1 highlight the role of MED12 in uterine leiomyomas.

Kämpjärvi K, Park MJ, Mehine M, Kim NH, Clark AD, Bützow R, Böhling T, Böhm J, Mecklin JP, Järvinen H, Tomlinson IP, van der Spuy ZM, Sjöberg J, Boyer TG, Vahteristo P.

Hum Mutat. 2014 Sep;35(9):1136-41. doi: 10.1002/humu.22612. Epub 2014 Jul 21.

PMID:
24980722
4.

Mutation analysis of components of the Mediator kinase module in MED12 mutation-negative uterine leiomyomas.

Mäkinen N, Heinonen HR, Sjöberg J, Taipale J, Vahteristo P, Aaltonen LA.

Br J Cancer. 2014 Apr 29;110(9):2246-9. doi: 10.1038/bjc.2014.138. Epub 2014 Mar 18.

5.

Oncogenic exon 2 mutations in Mediator subunit MED12 disrupt allosteric activation of cyclin C-CDK8/19.

Park MJ, Shen H, Spaeth JM, Tolvanen JH, Failor C, Knudtson JF, McLaughlin J, Halder SK, Yang Q, Bulun SE, Al-Hendy A, Schenken RS, Aaltonen LA, Boyer TG.

J Biol Chem. 2018 Mar 30;293(13):4870-4882. doi: 10.1074/jbc.RA118.001725. Epub 2018 Feb 13.

6.

Mutational analysis of MED12 exon 2 in uterine leiomyoma and other common tumors.

Je EM, Kim MR, Min KO, Yoo NJ, Lee SH.

Int J Cancer. 2012 Sep 15;131(6):E1044-7. doi: 10.1002/ijc.27610. Epub 2012 May 8.

7.

MED12 exon 2 mutations in histopathological uterine leiomyoma variants.

Mäkinen N, Vahteristo P, Kämpjärvi K, Arola J, Bützow R, Aaltonen LA.

Eur J Hum Genet. 2013 Nov;21(11):1300-3. doi: 10.1038/ejhg.2013.33. Epub 2013 Feb 27.

8.

MED12 and HMGA2 mutations: two independent genetic events in uterine leiomyoma and leiomyosarcoma.

Bertsch E, Qiang W, Zhang Q, Espona-Fiedler M, Druschitz S, Liu Y, Mittal K, Kong B, Kurita T, Wei JJ.

Mod Pathol. 2014 Aug;27(8):1144-53. doi: 10.1038/modpathol.2013.243. Epub 2014 Jan 3.

9.

Exomic landscape of MED12 mutation-negative and -positive uterine leiomyomas.

Mäkinen N, Vahteristo P, Bützow R, Sjöberg J, Aaltonen LA.

Int J Cancer. 2014 Feb 15;134(4):1008-12. doi: 10.1002/ijc.28410. Epub 2013 Aug 29.

10.

MED12 and uterine smooth muscle oncogenesis: State of the art and perspectives.

Croce S, Chibon F.

Eur J Cancer. 2015 Aug;51(12):1603-10. doi: 10.1016/j.ejca.2015.04.023. Epub 2015 May 30. Review.

PMID:
26037152
11.

Mediator complex subunit 12 exon 2 mutation analysis in different subtypes of smooth muscle tumors confirms genetic heterogeneity.

de Graaff MA, Cleton-Jansen AM, Szuhai K, Bovée JV.

Hum Pathol. 2013 Aug;44(8):1597-604. doi: 10.1016/j.humpath.2013.01.006. Epub 2013 Mar 19.

PMID:
23517922
12.

MED12 exon 2 mutations in phyllodes tumors of the breast.

Nagasawa S, Maeda I, Fukuda T, Wu W, Hayami R, Kojima Y, Tsugawa K, Ohta T.

Cancer Med. 2015 Jul;4(7):1117-21. doi: 10.1002/cam4.462. Epub 2015 Apr 13.

13.

Lack of evidence for frequent MED12 p.L1224F mutation in prostate tumours from Caucasian patients.

Stoehr R, Taubert H, Gaisa NT, Smeets D, Kneitz B, Giedl J, Ruemmele P, Wieland WF, Rau TT, Hartmann A.

J Pathol. 2013 Aug;230(4):453-6. doi: 10.1002/path.4208.

PMID:
23661306
14.

Highly heterogeneous genomic landscape of uterine leiomyomas by whole exome sequencing and genome-wide arrays.

Yatsenko SA, Mittal P, Wood-Trageser MA, Jones MW, Surti U, Edwards RP, Sood AK, Rajkovic A.

Fertil Steril. 2017 Feb;107(2):457-466.e9. doi: 10.1016/j.fertnstert.2016.10.035. Epub 2016 Nov 23.

PMID:
27889101
15.

MED12 mutation frequency in unselected sporadic uterine leiomyomas.

Heinonen HR, Sarvilinna NS, Sjöberg J, Kämpjärvi K, Pitkänen E, Vahteristo P, Mäkinen N, Aaltonen LA.

Fertil Steril. 2014 Oct;102(4):1137-42. doi: 10.1016/j.fertnstert.2014.06.040. Epub 2014 Aug 6.

PMID:
25108465
16.

MED12 alterations in both human benign and malignant uterine soft tissue tumors.

Pérot G, Croce S, Ribeiro A, Lagarde P, Velasco V, Neuville A, Coindre JM, Stoeckle E, Floquet A, MacGrogan G, Chibon F.

PLoS One. 2012;7(6):e40015. doi: 10.1371/journal.pone.0040015. Epub 2012 Jun 29.

17.

MED12, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas.

Mäkinen N, Mehine M, Tolvanen J, Kaasinen E, Li Y, Lehtonen HJ, Gentile M, Yan J, Enge M, Taipale M, Aavikko M, Katainen R, Virolainen E, Böhling T, Koski TA, Launonen V, Sjöberg J, Taipale J, Vahteristo P, Aaltonen LA.

Science. 2011 Oct 14;334(6053):252-5. doi: 10.1126/science.1208930. Epub 2011 Aug 25.

18.

Somatic MED12 mutations in uterine leiomyosarcoma and colorectal cancer.

Kämpjärvi K, Mäkinen N, Kilpivaara O, Arola J, Heinonen HR, Böhm J, Abdel-Wahab O, Lehtonen HJ, Pelttari LM, Mehine M, Schrewe H, Nevanlinna H, Levine RL, Hokland P, Böhling T, Mecklin JP, Bützow R, Aaltonen LA, Vahteristo P.

Br J Cancer. 2012 Nov 6;107(10):1761-5. doi: 10.1038/bjc.2012.428. Epub 2012 Sep 20.

19.

MED12 exon 2 mutations in uterine and extrauterine smooth muscle tumors.

Schwetye KE, Pfeifer JD, Duncavage EJ.

Hum Pathol. 2014 Jan;45(1):65-70. doi: 10.1016/j.humpath.2013.08.005. Epub 2013 Nov 4.

PMID:
24196187
20.

High-resolution melting analysis of MED12 mutations in uterine leiomyomas in Chinese patients.

Wang H, Ye J, Qian H, Zhou R, Jiang J, Ye L.

Genet Test Mol Biomarkers. 2015 Mar;19(3):162-6. doi: 10.1089/gtmb.2014.0273. Epub 2015 Jan 23.

Supplemental Content

Support Center